 HomeNewsSupply of high-quality Enzalutamide API and Intermediates

Supply of high-quality Enzalutamide API and Intermediates

2021-07-20

What is Enzalutamide ?

Enzalutamide are oral androgen like receptor antagonists. Currently, they have been approved by clinical research and FDA (Food and Drug Administration) for the treatment of metastatic castration tolerant prostate cancer after chemotherapy (i.e. patients with prostate cancer whose tumor or cancer cells are still growing after chemotherapy), which can prolong the survival of patients. The incidence rate of incidence of prostate cancer in the United States is very high. Nearly 240 thousand patients (the highest in all cancers) are newly added each year, and nearly 30 thousand deaths occur each year (second only to lung, breast and colorectal cancer). China has a low incidence rate. Enzalutamide is an androgen receptor inhibitor. Its target is different from cabataxel approved in 2010 and abiterone approved in 2011. It can competitively inhibit the binding of androgen and receptor, and inhibit the nuclear transport of androgen chemobook receptor and the interaction between androgen receptor and DNA, Enzalutamide can inhibit the proliferation of prostate cancer cells and induce their death. In the model experiment of xenotransplantation of prostate cancer in mice, enzalutamide can reduce the tumor volume. The main metabolite of enzalutamide is N-demethyl enzalutamide, which shows similar inhibitory activity in vitro as enzalutamide. The recommended dose for adults is 160 mg per day, which is absorbed rapidly after administration, The plasma concentration reached the highest level within 0.5-3 h, with an average terminal half-life of 5.8 D. the main metabolic enzymes were cyp2c8 and CYP3A4. The drug should not be used in combination with strong cyp2c8 inhibitors (such as gemfibrozil and gemfibrozil). If the drug needs to be administered together, the dose of enzalutamide should be reduced to 80 mg once a day.

Shandong Haohong Biotechnology Co., Ltd is mainly focuses on the development of anti-cancer, anti-diabets series of API and its advanced intermediates. The main products include Bicalutamide, enzalutamide, apalutamide, macitentan, cabozantinib, ceritinib, empagliflozin, tofacitinib citrate, and alectinib,etc. In line with the concept of "truth-seeking, innovation and integrity", we had exported our products to the United States, European countries, Japan, India, Bangladesh and other overseas markets. At present, Our company has dozens of advanced intermediates, all of which are commercialized.Enzalutamide is our top strong project.

Our Enzalutamide Intermediate list is as following, we have all the below intermedites offering all year.

enzalutamide

Enzalutamide-1 Enzalutamide-2 Enzalutamide-3

If you want to know more information about our company and products, please visit our website at http://www.haohongpharma.com. We will offer the best price and the best quality for you.

Previous: New research shows that even in your 80s, using your brain can help you avoid or delay Alzheimer's disease

Next: Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction

 HomeNewsSupply of high-quality Enzalutamide API and Intermediates

Shandong Haohong Biotechnology Co., Ltd.